|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-9-17
|
|
pubmed:abstractText |
There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary tumour to cytotoxic drug regimens. The goal of the study was to assess prospectively the predictive value of PAI-1 for response to first-line chemotherapy. PAI-1 concentration was measured on hypertonic cytosolic extracts (0.4 M potassium chloride) by ELISA before chemotherapy on a drill biopsy sample of the tumour in 69 T2 and T3 breast cancer patients (median age 46 years). Oestrogen receptor (ER) (51% ER+), progesterone receptor (PR) (58% PR+), S-phase (median 4.0%) and ploidy were also assessed in the majority of cases. The clinical response to treatment was evaluated after four cycles of FAC or FEC regimen (5-fluorouracil, epidoxorubicin or doxorubicin and cyclophosphamide) (one cycle every 4th week). PAI-1 could be assayed in 29 post-chemotherapy surgical samples. The objective response rate (complete response plus partial response) was 59% (41 out of 69). PAI-1 expressed as gram of tissue (range 19-2370 ng g(-1) tissue) was highly correlated (r = 0.98) to PAI-1 expressed as mg protein (range 0.5-68 ng mg(-1) protein). No correlation between PAI-1 level and response could be observed, with any cut-off. The post- and pre-chemotherapy PAI-1 levels were correlated (r = 0.66). Of all biological parameters, only high S-phase (cut-off 5%) was slightly correlated (chi2 = 3.91, P = 0.05) to response. These data suggest that PAI-1 is not a predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-13499785,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-1389510,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-1756272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-1911191,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-2402015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-2778823,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-3815294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-6361673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-7563153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-7857700,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-7904140,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-7908410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-7949209,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8080680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8240522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8260238,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8297742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8354119,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8388317,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8435475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8562150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8611670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-8625237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9275033-9816210
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
537-40
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
|
|
pubmed:affiliation |
Physiopathology Laboratory and Medical Oncology Department, Institute Curie, Paris, France.
|
|
pubmed:publicationType |
Journal Article
|
